A Phase 2 Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of VS-6063 in Subjects With Malignant Pleural Mesothelioma
Phase of Trial: Phase II
Latest Information Update: 03 May 2018
At a glance
- Drugs Defactinib (Primary)
- Indications Mesothelioma
- Focus Registrational; Therapeutic Use
- Acronyms COMMAND
- Sponsors Verastem Oncology
- 03 May 2018 According to a Verastem Oncology media release, Verastem changed its name to Verastem Oncology.
- 18 Aug 2016 This trial has been completed in Belgium as per European Clinical Trials Database record.
- 06 Oct 2015 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.